Company news

Novavax, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

July 10, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

July 4, 2022

Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

June 27, 2022

Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

June 22, 2022

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

June 22, 2022

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

June 12, 2022

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

June 6, 2022

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

May 8, 2022

Novavax to Participate in BofA Securities 2022 Healthcare Conference

May 3, 2022

Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022

May 1, 2022

Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial

April 21, 2022

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

April 19, 2022

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

April 18, 2022

Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

April 17, 2022

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

April 12, 2022

Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand

April 7, 2022

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)

March 30, 2022

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine

March 24, 2022

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

March 21, 2022

Novavax Announces Launch of Global Vaccine Education Programs

March 9, 2022

Novavax to Participate in Cowen's 42nd Annual Health Care Conference

March 1, 2022

Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

February 27, 2022

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

February 27, 2022

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022

February 20, 2022

Health Canada Authorizes Novavax COVID-19 Vaccine

February 16, 2022

Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine

February 13, 2022

Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland

February 13, 2022

Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

February 9, 2022

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

February 2, 2022

Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*

February 2, 2022

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

January 30, 2022

Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine

January 27, 2022

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

January 18, 2022

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

January 11, 2022

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa

January 9, 2022

Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine

December 30, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

December 27, 2021

Novavax and SK bioscience Expand Manufacturing Agreement

December 22, 2021

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

December 21, 2021

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

December 20, 2021

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study

December 20, 2021

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

December 19, 2021

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

December 19, 2021

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

December 19, 2021

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

December 16, 2021

Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine

December 14, 2021

Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates

December 12, 2021

Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore

November 23, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 69 decks. Every deck is listed under its year.